Financing Comparative Effectiveness Research
You may also be interested in...
The administration's 2012 budget proposal increases AHRQ funds for comparative effectiveness research by $600,000 to $21.6 million plus $24 million expected to be transferred from the Patient-Centered Outcomes Research Institute Trust Fund.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials